Published Date: 12/19/2024

Value proposition: Novel method used to detect tau proteins in the brain using biofluids.

Technology Description

Researchers at Washington University in St. Louis have developed a method to identify and differentiate primary and secondary tauopathies in the brain. Many neurological disorders are characterized by protein aggregation in the brain. The brain aggregation of Tau protein is characterized by neuropathology in patients with Alzheimer Disease (AD), Progressive Supranuclear Palsy, Corticobasal Degeneration (CBD), Pick disease (PiD), Chronic Traumatic Encephalopathy (CTE), and others. Currently, there is no accurate method to detect abnormal tau proteins other than a brain autopsy.

This method uses tau from biofluid to separate several classes of tauopathies, improving the diagnostic procedures for neurodegenerative disorders.

Applications

• Diagnosis of abnormal tau protein in the brain

Key Advantages

• Less invasive method to detect tau proteins
• Uses biofluid to differentiate primary and secondary tauopathies

Patents

Patent application filed

Related Web Links – Nicolas Barthelemy Profile